JP2022089845A - 抗炎症性腸疾患の作用を有する医薬、その調製方法および使用 - Google Patents
抗炎症性腸疾患の作用を有する医薬、その調製方法および使用 Download PDFInfo
- Publication number
- JP2022089845A JP2022089845A JP2022048441A JP2022048441A JP2022089845A JP 2022089845 A JP2022089845 A JP 2022089845A JP 2022048441 A JP2022048441 A JP 2022048441A JP 2022048441 A JP2022048441 A JP 2022048441A JP 2022089845 A JP2022089845 A JP 2022089845A
- Authority
- JP
- Japan
- Prior art keywords
- group
- inflammatory bowel
- formula
- action
- bowel disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 89
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 48
- 230000009471 action Effects 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 229940002612 prodrug Drugs 0.000 claims abstract description 8
- 239000000651 prodrug Substances 0.000 claims abstract description 8
- 239000012453 solvate Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 67
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- -1 benzoylcyclopropylamino group Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 239000008177 pharmaceutical agent Substances 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 239000012038 nucleophile Substances 0.000 claims description 8
- 238000007254 oxidation reaction Methods 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical group OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000007800 oxidant agent Substances 0.000 claims description 6
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical group NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical group NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000004278 EU approved seasoning Substances 0.000 claims description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940117975 chromium trioxide Drugs 0.000 claims description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 claims description 2
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 235000011194 food seasoning agent Nutrition 0.000 claims description 2
- 229910003002 lithium salt Inorganic materials 0.000 claims description 2
- 159000000002 lithium salts Chemical class 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 50
- 241000700159 Rattus Species 0.000 description 29
- 238000010586 diagram Methods 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 210000002540 macrophage Anatomy 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 19
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 15
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 15
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 15
- SBGBAZQAEOWGFT-OAHLLOKOSA-N myricanol Chemical class C=1C2=C(OC)C(OC)=C(O)C=1CCCC[C@@H](O)CCC1=CC=C(O)C2=C1 SBGBAZQAEOWGFT-OAHLLOKOSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 210000001072 colon Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 210000000664 rectum Anatomy 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 208000025865 Ulcer Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 231100000397 ulcer Toxicity 0.000 description 9
- 101000605172 Aspergillus niger (strain CBS 513.88 / FGSC A1513) Probable endopolygalacturonase E Proteins 0.000 description 8
- 101000605171 Aspergillus niger Endopolygalacturonase E Proteins 0.000 description 8
- 101000941281 Bos taurus Gastric triacylglycerol lipase Proteins 0.000 description 8
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 8
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 8
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 8
- 235000002597 Solanum melongena Nutrition 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 7
- 229960004963 mesalazine Drugs 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- JVNMAWOIOBZQLC-UHFFFAOYSA-N Myricanol Natural products COC1=C2CCCCCC(O)CCc3ccc(O)c(c3)C(=C(OC)C1=O)C2=O JVNMAWOIOBZQLC-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 235000009134 Myrica cerifera Nutrition 0.000 description 3
- 244000061457 Solanum nigrum Species 0.000 description 3
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000013375 chromatographic separation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241001115514 Myricaceae Species 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 206010036775 Rectal inflammations Diseases 0.000 description 1
- 206010038080 Rectal ulcer Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical group 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 125000006278 bromobenzyl group Chemical group 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/14—Acetic acid esters of monohydroxylic compounds
- C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
- C07C69/157—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C305/00—Esters of sulfuric acids
- C07C305/20—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
R3は水素、アセチル基、スルホン酸基、またはリン酸基から選ばれるいずれか1種であり、
式Iにおいて、R1、R2およびR3が同時に水素ではなく、R1、R2およびR3が同時にアセチル基ではなく、R1およびR2が同時にベンジル基ではないことと、式IIにおいて、R1およびR2が同時に水素またはベンジル基ではないこととを満たす。)
以下の反応式のように、式IIIで表される化合物ミリカノールが、塩基性試薬の存在下で求核試薬と置換反応を経て式Iで表される化合物を得ることを含む調製方法を提供する。
R3は水素、アセチル基、スルホン酸基、またはリン酸基から選ばれるいずれか1種であり、
R1、R2およびR3が同時に水素ではなく、R1、R2およびR3が同時にアセチル基ではなく、R1およびR2が同時にベンジル基ではないことを満たす。)
以下の反応式のように、式IVで表される化合物が、酸化剤の存在下で酸化反応により式IIで表される化合物を得ることを含む調製方法を更に提供する。
R1およびR2が同時に水素またはベンジル基ではないことを満たす。)
本実施例は以下の方法により、5,17-ジアセトキシミリカノールを調製した。
本実施例は以下の方法により、5-n-プロポキシミリカノールを調製した。
本実施例は以下の方法により、5-ベンジルオキシミリカノールを調製した。
本実施例は以下の方法により、5,17-ジアリルオキシミリカノールを調製した。
本実施例は以下の方法により、5-アリルオキシミリカノールを調製した。
本実施例は以下の方法により、5,17-アリルオキシミリセチンを調製した。
本実施例は以下の方法により、5-アセトキシミリカノールを調製した。
本実施例は以下の方法により、11-スルホニルオキシミリカノールを調製した。
本実施例は以下の方法により、5,17-ジアセトキシミリセチンを調製した。
本実施例において、実施例1~8で調製した化合物A~Hに対してインビトロ抗炎症活性テストを行った。
本実施例において、ミリカノール誘導体化合物Hの、デキストラン硫酸ナトリウム(DSS)により誘導されたIBDマウスインビボモデルに対するインビボにおける薬力学的活性をテストした。
本実施例において、化合物Hの、2,4,6-トリニトロベンゼンスルホン酸(TNBS)により誘導されたIBDラットインビボモデルに対するインビボにおける薬力学的活性をテストした。
本実施例において、化合物A、B、Gおよび化合物Hの急性毒性をテストし、具体的なステップは以下のとおりである。
Claims (15)
- 抗炎症性腸疾患の作用を有する医薬であって、式Iまたは式IIで表される構造を有する、医薬。
R3は水素、アセチル基、スルホン酸基、またはリン酸基から選ばれるいずれか1種であり、
式Iにおいて、R1、R2およびR3が同時に水素ではなく、R1、R2およびR3が同時にアセチル基ではなく、R1およびR2が同時にベンジル基ではないことと、式IIにおいて、R1およびR2が同時に水素またはベンジル基ではないこととを満たす。) - 式Iで表される構造を有する、抗炎症性腸疾患の作用を有する医薬の調製方法であって、
以下の反応式のように、式IIIで表される化合物ミリカノールが、塩基性試薬の存在下で求核試薬と置換反応を経て式Iで表される化合物を得ることを含む、調製方法。
R3は水素、アセチル基、スルホン酸基、またはリン酸基から選ばれるいずれか1種であり、
R1、R2およびR3が同時に水素ではなく、R1、R2およびR3が同時にアセチル基ではなく、R1およびR2が同時にベンジル基ではないことを満たす。) - 前記式IIIで表される化合物ミリカノールと求核試薬とのモル比は1:(1~6)であり、
好ましくは、前記置換反応の溶媒は、ジクロロメタン、テトラヒドロフラン、アセトニトリル、ピリジン、またはトリエチルアミンのうちのいずれか1種または少なくとも2種の組み合わせを含み、
好ましくは、前記置換反応の温度は0~80℃であり、
好ましくは、前記置換反応の時間は1~30hであり、
好ましくは、前記塩基性試薬は、ピリジン、トリエチルアミン、N,N-ジイソプロピルエチルアミン、N-メチルモルホリン、炭酸カリウム、炭酸ナトリウム、炭酸セシウム、水酸化カリウム、水酸化ナトリウム、またはカリウム-t-ブトキシドのうちのいずれか1種または少なくとも2種の組み合わせを含み、ピリジンまたはトリエチルアミンであることが好ましい、請求項3に記載の調製方法。 - 式IIで表される構造を有する、抗炎症性腸疾患の作用を有する医薬の調製方法であって、
以下の反応式のように、式IVで表される化合物が、酸化剤の存在下で酸化反応により式IIで表される化合物を得ることを含む、調製方法。
R1およびR2が同時に水素またはベンジル基ではないことを満たす。) - 前記式IVで表される化合物と酸化剤とのモル比は1:(0.5~5)であり、
好ましくは、前記酸化剤は、クロロクロム酸ピリジニウム塩、三酸化クロム、オゾン、 過酸化水素水、または三酸化硫黄のいずれか1種または少なくとも2種の組み合わせを含み、
好ましくは、前記酸化反応の溶媒は、ジクロロメタン、テトラヒドロフラン、トルエン、N,N-ジメチルホルムアミド、n-ヘプタン、またはジメチルスルホキシドのうちのいずれか1種または少なくとも2種の組み合わせを含み、
好ましくは、前記酸化反応の温度は0~50℃であり、
好ましくは、前記酸化反応の時間は1~10hである、請求項5に記載の調製方法。 - 請求項1または2に記載の抗炎症性腸疾患の作用を有する医薬の医薬的に許容される塩。
- 前記医薬的に許容される塩は、式Iで表される化合物の金属塩または式IIで表される化合物の金属塩であり、
好ましくは、前記金属塩は、リチウム塩、ナトリウム塩、カリウム塩、マグネシウム塩、またはカルシウム塩のうちのいずれか1種を含み、ナトリウム塩またはカリウム塩であることが好ましい、請求項7に記載の医薬的に許容される塩。 - 請求項1または2に記載の抗炎症性腸疾患の作用を有する医薬の溶媒和物。
- 前記溶媒和物は、式Iで表される化合物の水和物、式Iで表される化合物のアルコール和物、式IIで表される化合物の水和物、または式IIで表される化合物のアルコール和物である、請求項9に記載の溶媒和物。
- 請求項1または2に記載の抗炎症性腸疾患の作用を有する医薬の互変異性体もしくは立体化学異性体。
- 請求項1または2に記載の抗炎症性腸疾患の作用を有する医薬のプロドラッグ。
- 請求項1または2に記載の抗炎症性腸疾患の作用を有する医薬を含む、医薬組成物。
- 前記医薬組成物は補助材料を更に含み、
好ましくは、前記補助材料は、賦形剤、希釈剤、担体、調味剤、粘着剤、または充填剤のうちのいずれか1種または少なくとも2種の組み合わせを含み、
好ましくは、前記抗炎症性腸疾患の医薬組成物の剤形は、経口投与製剤、外用製剤、または非経口投与製剤のうちのいずれか1種を含む、請求項13に記載の医薬組成物。 - 請求項1または2に記載の抗炎症性腸疾患の作用を有する医薬、請求項7または8に記載の抗炎症性腸疾患の作用を有する医薬の医薬的に許容される塩、請求項9または10に記載の抗炎症性腸疾患の作用を有する医薬の溶媒和物、請求項11に記載の抗炎症性腸疾患の作用を有する医薬の互変異性体もしくは立体化学異性体、請求項12に記載の抗炎症性腸疾患の作用を有するプロドラッグ、あるいは請求項13または14に記載の医薬組成物の、炎症性腸疾患を治療する医薬の調製における使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022048441A JP2022089845A (ja) | 2018-07-28 | 2022-03-24 | 抗炎症性腸疾患の作用を有する医薬、その調製方法および使用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020524059A JP7332167B2 (ja) | 2018-07-28 | 2018-07-28 | 抗炎症性腸疾患の作用を有する医薬、その調製方法および使用 |
PCT/CN2018/097685 WO2020024078A1 (zh) | 2018-07-28 | 2018-07-28 | 一种具有抗炎症性肠病作用的药物及其制备方法和应用 |
JP2022048441A JP2022089845A (ja) | 2018-07-28 | 2022-03-24 | 抗炎症性腸疾患の作用を有する医薬、その調製方法および使用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020524059A Division JP7332167B2 (ja) | 2018-07-28 | 2018-07-28 | 抗炎症性腸疾患の作用を有する医薬、その調製方法および使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022089845A true JP2022089845A (ja) | 2022-06-16 |
Family
ID=69230479
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020524059A Active JP7332167B2 (ja) | 2018-07-28 | 2018-07-28 | 抗炎症性腸疾患の作用を有する医薬、その調製方法および使用 |
JP2022048441A Pending JP2022089845A (ja) | 2018-07-28 | 2022-03-24 | 抗炎症性腸疾患の作用を有する医薬、その調製方法および使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020524059A Active JP7332167B2 (ja) | 2018-07-28 | 2018-07-28 | 抗炎症性腸疾患の作用を有する医薬、その調製方法および使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11602514B2 (ja) |
EP (1) | EP3756660A4 (ja) |
JP (2) | JP7332167B2 (ja) |
CN (1) | CN111315370B (ja) |
WO (1) | WO2020024078A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115505021B (zh) * | 2021-06-23 | 2023-08-15 | 沈阳药科大学 | 具有炎症性肠病治疗作用的乌苏酸衍生物及其制备方法和用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105198714A (zh) * | 2015-08-14 | 2015-12-30 | 浙江省中医药研究院 | 杨梅醇衍生物及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6790979B2 (en) * | 2002-04-17 | 2004-09-14 | University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
JP4343268B2 (ja) | 2007-12-18 | 2009-10-14 | 明治製菓株式会社 | 炎症性腸疾患の予防または治療剤 |
US8940945B2 (en) | 2010-07-23 | 2015-01-27 | University Of South Florida | Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases |
CN102552243A (zh) | 2012-02-29 | 2012-07-11 | 浙江省中医药研究院 | 杨梅醇和/或杨梅酮在制备抗肿瘤药物中的应用 |
CN108434127B (zh) | 2018-06-14 | 2020-01-17 | 苏州沪云肿瘤研究中心股份有限公司 | 一种杨梅醇和/或杨梅酮在制备具有预防和/或治疗炎症性肠病的药物中的应用 |
-
2018
- 2018-07-28 CN CN201880070394.4A patent/CN111315370B/zh active Active
- 2018-07-28 WO PCT/CN2018/097685 patent/WO2020024078A1/zh unknown
- 2018-07-28 JP JP2020524059A patent/JP7332167B2/ja active Active
- 2018-07-28 US US17/043,428 patent/US11602514B2/en active Active
- 2018-07-28 EP EP18928374.0A patent/EP3756660A4/en active Pending
-
2022
- 2022-03-24 JP JP2022048441A patent/JP2022089845A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105198714A (zh) * | 2015-08-14 | 2015-12-30 | 浙江省中医药研究院 | 杨梅醇衍生物及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
J NAT PROD, vol. 75, JPN6021011145, 2012, pages 1798 - 1802, ISSN: 0005057303 * |
Also Published As
Publication number | Publication date |
---|---|
CN111315370A (zh) | 2020-06-19 |
EP3756660A1 (en) | 2020-12-30 |
US20210015780A1 (en) | 2021-01-21 |
US11602514B2 (en) | 2023-03-14 |
JP7332167B2 (ja) | 2023-08-23 |
EP3756660A4 (en) | 2021-10-13 |
JP2021501171A (ja) | 2021-01-14 |
CN111315370B (zh) | 2023-09-29 |
WO2020024078A1 (zh) | 2020-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7119119B2 (en) | Immunoregulatory compounds and derivatives and methods of treating diseases therewith | |
ES2780825T3 (es) | Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis del hígado, la fibrosis de la piel y la fibrosis cardíaca | |
US8026282B2 (en) | Phenoxyalkylcarboxylic acid derivatives in the treatment of irritable bowel syndrome | |
JP6162133B2 (ja) | 潰瘍性大腸炎を抑制するプロトベルベリン生物学的アルカロイド誘導体およびその使用 | |
JPH0469338A (ja) | 炎症性腸疾患予防・治療剤 | |
JP2022089845A (ja) | 抗炎症性腸疾患の作用を有する医薬、その調製方法および使用 | |
JPH0131484B2 (ja) | ||
WO2008131586A1 (en) | Uses of 5-methyl-1-(substituted phenyl)-2(1h)-pyridones as anti-inflammatory and tnf-alpha-blocking agents | |
CN101570528B (zh) | 甘草素衍生物及其制法和用途 | |
US4134989A (en) | Guaiacol p-isobutyl hydratropate | |
US11925634B2 (en) | Use of koumine in preparation of medicament for treatment of inflammatory bowel disease | |
JPH06509110A (ja) | 胃及び十二指腸障害を治療する方法及び組成物並びに新規なpge↓2誘導体 | |
RU2601307C2 (ru) | Инденовые производные для применения в лечении воспалительного заболевания кишечника | |
CN112826820B (zh) | Nlrp3抑制剂及其应用 | |
CN112168831B (zh) | 一个雷公藤内酯醇衍生物在防治炎症性肠病中的用途 | |
WO2021036495A1 (zh) | 新型苯乙酸衍生物、其制备方法及其作为药物的用途 | |
US20210052537A1 (en) | Colitis ameliorating agent | |
JP2008543741A (ja) | 新規な化合物 | |
CA3182245A1 (en) | Pharmaceutical composition comprising benzimidazole derivative compound | |
CN118005709A (zh) | 基于偶氮还原酶激活的CDDO-Me/Ozanimod共前药及其制备方法和应用 | |
CN117551085A (zh) | 一种苯并吡喃查尔酮类化合物、制备方法和应用及其药物制剂 | |
JP2019142815A (ja) | 心不全改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220425 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230815 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240205 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240603 |